LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

Home・Aandelen Lijst・Immunocore Holdings PLC ADR

Immunocore Holdings PLC ADR

Gesloten

29.05 0.83

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

27.46

Max

29.38

Belangrijke statistieken
By Trading Economics
Inkomsten	-30M -30M
Verkoop	-26M 77M
Winstmarge	-38.823
Werknemers	524
EBITDA	-12M -8M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+116.05% upside

Dividenden
By Dow Jones
Volgende Winsten	6 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-214M 1.4B
Vorige openingsprijs	28.22
Vorige sluitingsprijs	29.05

Technische score

By Trading Central

Vertrouwen

Weak Bearish Evidence

27.895 / 30.16 Steun & Weerstand

Immunocore Holdings PLC ADR Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

11 mei 2026, 22:15 UTC

Acquisities, Fusies, Overnames

BMO Financial Group to Sell Transportation-, Vendor-Finance Businesses to Stonepeak

11 mei 2026, 23:46 UTC

Marktinformatie

Yen Consolidates as Traders Await Bessent's Meetings -- Market Talk

11 mei 2026, 23:44 UTC

Marktinformatie

Nikkei May Rise on AI Enthusiasm -- Market Talk

11 mei 2026, 23:33 UTC

Marktinformatie

Gold Rises on Possible Position Adjustments -- Market Talk

11 mei 2026, 22:37 UTC

Marktinformatie

CSL's Profit, Revenue Downgrade 'Not a Complete Surprise' -- Market Talk

11 mei 2026, 22:32 UTC

Winsten

Verde Clean Fuels 1Q Loss/Shr 5c >VGAS

11 mei 2026, 22:02 UTC

Marktinformatie

Stellar Auto Sales Increase in Canada Could Be Tied to Return of EV Incentives -- Market Talk

11 mei 2026, 21:49 UTC

Winsten

Rigetti Computing Revenue Triples. Why the Quantum Stock Is Falling. -- Barrons.com

11 mei 2026, 21:42 UTC

Marktinformatie

Declining Hours Worked Should Keep Bank of Canada Firmly on Hold -- Market Talk

11 mei 2026, 21:32 UTC

Acquisities, Fusies, Overnames

Bank of Montreal to Sell Transportation Finance and Vendor Finance Businesses to Stonepeak

11 mei 2026, 21:32 UTC

Acquisities, Fusies, Overnames

BMO: Supports Strategy to Elevate Returns and Accelerate Growth, Transaction Accretive to Cap Ratios and ROE >BMO.T

11 mei 2026, 21:32 UTC

Acquisities, Fusies, Overnames

BMO: Positions Businesses for Continued Growth in Efficient Cap Structure >BMO.T

11 mei 2026, 21:32 UTC

Acquisities, Fusies, Overnames

BMO: To Invest in 19.9% Equity Interest, Enabling Continued Participation in the Businesses' Long-Term Value Creation >BMO.T

11 mei 2026, 21:31 UTC

Acquisities, Fusies, Overnames

BMO: Announces Strategic Sale of Transportation and Vendor Finance Businesses

11 mei 2026, 21:23 UTC

Acquisities, Fusies, Overnames

CSG Systems Sale to NEC Gets CFIUS Clearance

11 mei 2026, 21:12 UTC

Winsten

Ovintiv: Full-Yr Production Volumes Expected to Avg 620 to 645 MBOE/d, Full-Yr Expected Cap Investment of $2.25B to $2.35B >OVV

11 mei 2026, 21:12 UTC

Winsten

Ovintiv 1Q Loss/Shr $2.35 >OVV

11 mei 2026, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

11 mei 2026, 20:44 UTC

Winsten

Steris: Board Approves New $1B Shr Repurchase Program >STE

11 mei 2026, 20:43 UTC

Winsten

Whirlpool Shares Are Still Falling. Last Week's Earnings Might Be Why. -- Barrons.com

11 mei 2026, 20:32 UTC

Winsten

CleanSpark 2Q Loss/Shr $1.52 >CLSK

11 mei 2026, 20:32 UTC

Winsten

CleanSpark 2Q Rev $136.4M >CLSK

11 mei 2026, 20:30 UTC

Winsten

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

11 mei 2026, 20:30 UTC

Winsten

Steris 4Q Cont Ops EPS $2.24 >STE

11 mei 2026, 20:30 UTC

Winsten

Steris 4Q Rev $1.6B >STE

11 mei 2026, 20:30 UTC

Winsten

Steris Sees FY Adj EPS $11.10-Adj EPS $11.30 >STE

11 mei 2026, 20:30 UTC

Winsten

Steris 4Q Adj EPS $2.83 >STE

11 mei 2026, 20:22 UTC

Populaire aandelen

Stocks to Watch: Moderna, Intel, Micron, Fox -- WSJ

11 mei 2026, 19:37 UTC

Winsten

More Bad News at KKR's Private Credit Fund -- Barrons.com

11 mei 2026, 19:32 UTC

Marktinformatie

Oil Gains As Trump Rejects Iran's Response to U.S. Plan -- Market Talk

Peer Vergelijking

Prijswijziging

Immunocore Holdings PLC ADR Prognose

Koersdoel

By TipRanks

116.05% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 62.33 USD 116.05%

Hoogste 100 USD

Laagste 33 USD

Gebaseerd op 10 Wall Street-analisten die 12-maands prijsdoelen bieden voor Immunocore Holdings PLC ADR - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

10 ratings

Buy

Hold

Sell

Gebaseerd op 10 analisten die aandelenratings hebben gegeven aan Immunocore Holdings PLC ADR - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

27.895 / 30.16Steun & Weerstand

Recent bearish events outweigh bullish events.

There is one bearish event.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Immunocore Holdings PLC ADR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.